Interestingly, in addition to loss of the higher mobility Fra-2 band, we observed enhanced mobility of all the immunoreactive Fra-2 after CIP treatment, suggesting that Fra-2 exists in various states of phosphorylation (Figure 1d). The gene discussed is FOSL2; the disease is hereditary sensory and autonomic neuropathy.